Medication Assistance (REACH)

Reach logo

REACH^TM (which stands for Resources, Education and Access for patients with Chorea associated with Huntington's disease) is a comprehensive assistance program designed to help patients who may benefit from Xenazine therapy manage their medication cost and get access to Xenazine.

It is an integral part of the Lundbeck Inc. (the makers of Xenazine) commitment to help ensure that patients have access to Xenazine as quickly as possible. The various REACH services help eliminate potential barriers to getting your medication that may include administrative difficulty and financial need.

Depending upon your insurance coverage and financial need, REACH offers a variety of support.

Reimbursement Support
The Xenazine Information Center (XIC) employs a dedicated team of experienced specialists who assist patients in navigating third-party payer requirements including verifying coverage, facilitating prior authorization and assisting with any necessary appeals.
Patient Assistance
Assistance with free medication is available for eligible or qualified patients with demonstrated financial need. The XIC will determine if you qualify.
Co-pay/Co-insurance Assistance
Assistance with coverage of co-pay or co-insurance amounts is available. The XIC will determine if you qualify.
Patient Starter Rx (prescription supply)
In some cases, the XIC will send patients a starter prescription within 15 days of receipt of the completed Xenazine Treatment Form , while insurance authorization and reimbursement status are still pending.

If you have questions concerning your ability to pay for your Xenazine prescription, you can call the Xenazine Information Center (XIC) at 1-888-882-6013. In some cases, the XIC will also call you if they need additional information related to your prescription.

XENAZINE® (tetrabenazine) Tablets

Indications and Usage:

Xenazine is a medicine that is used to treat the involuntary movements (chorea) of Huntington’s disease. Xenazine does not cure the cause of the involuntary movements, and it does not treat other symptoms of Huntington’s disease, such as problems with thinking or emotions.

It is not known whether Xenazine is safe and effective in children.

Important Safety Information:

Xenazine can increase the chance of depression, suicidal thoughts or suicidal actions in some patients.
You should not start taking Xenazine if you are depressed (have untreated depression or depression that is not well controlled by medicine) or have suicidal thoughts.
Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts or feelings. This is especially important when Xenazine is started and when the dose is changed.

Do not take Xenazine if you have liver problems or are taking monoamine oxidase inhibitors or reserpine. At least 20 days should pass after stopping reserpine before starting Xenazine. Tell your doctor if you are pregnant, breast-feeding or have breast cancer.

The need for therapy should be evaluated on an ongoing basis with your doctor. The dose of Xenazine should be adjusted slowly over several weeks for a dose that is appropriate for you. If your doctor thinks you need to take more than 50 mg of Xenazine each day, you will need to have a blood test to see if Xenazine is safe for you.

Neuroleptic malignant syndrome (NMS), restlessness, agitation, parkinsonism (slight shaking, body stiffness, trouble moving or keeping your balance), trouble swallowing, dizziness, and irregular heartbeat have also been reported with use of Xenazine. Do not use Xenazine with drugs known to cause irregular heart beat. Side effects associated with Xenazine, such as irregular heartbeat, NMS, and parkinsonism, may be increased if used together with drugs called dopamine antagonists. Uncontrolled movements called tardive dyskinesia (TD) may develop in patients treated with Xenazine. It is possible that the TD will not go away.

Xenazine may cause sleepiness or drowsiness, and may affect the ability to drive or use dangerous machinery. Some side effects, such as depression, tiredness, trouble sleeping, sleepiness/drowsiness, parkinsonism, and restlessness, may be dose-dependent. If the side effects don’t stop or lessen, your doctor should consider lowering the dose or stopping your Xenazine. The most commonly reported side effects in studies with Xenazine were sleepiness/drowsiness, tiredness, trouble sleeping, depression, restlessness, anxiety, and nausea.

For more information, please see the Xenazine Medication Guide and Full Prescribing Information, including Boxed Warning.

®Xenazine is a registered trademark of Biovail Laboratories International (Barbados) S.R.L.

XZN118

The product information provided in this site is intended only for residents of the U.S. The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider.